Related Experiment Video

Updated: Sep 25, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.9K

Dual Temozolomide and ICI Treatment Is Efficacious and Safe in MSS mCRC

    Cancer Discovery
    |May 2, 2022
    PubMed

    Abstract:

    Patients with MSS and MGMT-depleted mCRC exhibited clinical benefit post-temozolomide and ICI treatment.

    More Related Videos

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
    08:00

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

    Published on: April 16, 2019

    18.4K
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.5K

    Related Experiment Videos

    Last Updated: Sep 25, 2025

    A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
    05:29

    A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

    Published on: March 28, 2021

    2.9K
    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
    08:00

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

    Published on: April 16, 2019

    18.4K
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.5K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.4K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.4K

    Articles linked to this work by shared authors, journal, and citation graph.

    Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.

    Cancer discovery·2026

    Phase III Trials Test First-Line Options in Advanced NSCLC.

    Cancer discovery·2026

    How a Rare Inherited Lung Cancer Mutation Took Root in Appalachia.

    Cancer discovery·2026

    Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.

    Cancer discovery·2026

    Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia.

    Cancer discovery·2026

    Nucleoporins in Cancer: Functional Roles and Therapeutic Opportunities.

    Cancer discovery·2026

    A case of tic improvement following tipepidine administration in a boy with Tourette syndrome comorbid with attention-deficit/hyperactivity disorder and autism spectrum disorder.

    PCN reports : psychiatry and clinical neurosciences·2026

    Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics.

    Research and practice in thrombosis and haemostasis·2026

    Efficacy and safety of different TPO-RAs combined with cyclosporine in the treatment of NSAA.

    Therapeutic advances in hematology·2026

    Mesenchymal Stem Cell-Derived Extracellular Vesicles Ameliorate NaIO3-Induced Dry AMD by Delivering miR-486-3p to Inhibit Lipocalin-2-Mediated Ferroptosis.

    MedComm·2026

    Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study.

    Frontiers in immunology·2026

    Agomelatine as augmentation therapy with second-generation antipsychotics for negative symptoms of schizophrenia: An open-label randomised clinical trial and electroencephalogram-derived model for treatment response prediction.

    General psychiatry·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us